DermTech (NASDAQ:DMTK) reported Q2 EPS of ($0.99), $0.02 better than the analyst estimate of ($1.01). Revenue for the quarter came in at $4.2 million versus the consensus estimate of $4.82 million.
DermTech (NASDAQ:DMTK) reported Q2 EPS of ($0.99), $0.02 better than the analyst estimate of ($1.01). Revenue for the quarter came in at $4.2 million versus the consensus estimate of $4.82 million.